Stanley Musial has more than 25 years of financial leadership experience in the life sciences industry.
Read more...
While serving as the CFO of various life sciences companies, he successfully securing several major financing rounds, transforming companies from development stage to commercial organizations, and negotiating several transactions, including asset licensing deals and mergers and acquisitions.
Prior to joining Xenikos, Musial served as the Chief Financial Officer of several pharmaceutical and biotech companies, including EryDel SpA, Egalet, Inc. (which he took public on NASDAQ in 2014), Prism Pharmaceuticals, Inc. (acquired in 2011 by Baxter International), and Strategic Diagnostics, Inc. Musial received a BS in accounting from The Pennsylvania State University and his MBA from Temple University, and he is a Certified Public Accountant in the Commonwealth of Pennsylvania.